Get the Stockscreener App
280.06
0.41%
-1.16
Pre-market:
278.19
-1.87
-0.67%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $280.06, with a volume of 2.78M.
It is down -0.41% in the last 24 hours and down -4.87% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$281.22
Open:
$281.57
24h Volume:
2.78M
Relative Volume:
0.92
Market Cap:
$152.22B
Revenue:
$34.13B
Net Income/Loss:
$5.93B
P/E Ratio:
25.55
EPS:
10.96
Net Cash Flow:
$10.92B
1W Performance:
-1.07%
1M Performance:
-4.87%
6M Performance:
-12.29%
1Y Performance:
-10.03%
1-Day Range:
$276.09
$281.97
1-Week Range:
$275.19
$292.00
52-Week Range:
$253.30
$346.85
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
280.06 | 152.22B | 34.13B | 5.93B | 10.92B | 10.96 |
|
LLY
Lilly Eli Co
|
821.46 | 737.81B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
155.00 | 370.90B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
196.07 | 340.25B | 57.37B | 4.20B | 17.83B | 2.35 |
|
NVO
Novo Nordisk Adr
|
69.12 | 277.97B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
113.08 | 222.45B | 53.22B | 12.86B | 14.85B | 6.39 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen (AMGN) Stock: Waiting Patiently For A Real Catalyst - Seeking Alpha
Baird Financial Group Inc. Decreases Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Alethea Capital Management LLC Makes New Investment in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Aptus Capital Advisors LLC Acquires 16,380 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Ancora Advisors LLC Acquires 1,189 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
PDT Partners LLC Increases Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Regeneron, Amgen Open Drug 'Bundling' Trial In Del. - Law360
Bison Wealth LLC Trims Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Accredited Wealth Management LLC Makes New $847,000 Investment in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen (NASDAQ:AMGN) Releases Earnings Results - MarketBeat
Is Trending Stock Amgen Inc. (AMGN) a Buy Now? - Yahoo
AMGN's Key Drugs Repatha, Evenity & Blincyto Drive Q1 Sales Growth - TradingView
Alteri Wealth LLC Buys Shares of 11,903 Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Aristotle Capital Management LLC Has $1.01 Billion Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Axa S.A. Has $70.81 Million Stake in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Stock Outlook: Is Wall Street Bullish Or Bearish? - Barchart.com
Caisse DE Depot ET Placement DU Quebec Sells 144,409 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Red Biotechnology Market to Witness Remarkable Growth with - openPR.com
Marshall Wace LLP Decreases Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
The Manufacturers Life Insurance Company Sells 27,512 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Mercer Global Advisors Inc. ADV Buys Shares of 116,537 Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen: Reducing My Price Target, Reiterate Buy After A Solid Q1 - Seeking Alpha
Meiji Yasuda Life Insurance Co Has $6.05 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
California State Teachers Retirement System Sells 23,730 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Comerica Bank Has $48.74 Million Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Position Trimmed by Public Employees Retirement Association of Colorado - MarketBeat
Northern Trust Corp Has $1.68 Billion Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
1,826 Shares in Amgen Inc. (NASDAQ:AMGN) Bought by Marshall & Sterling Wealth Advisors Inc. - MarketBeat
Beacon Pointe Advisors LLC Lowers Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Arrow Financial Corp Raises Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
1,825 Shares in Amgen Inc. (NASDAQ:AMGN) Purchased by Westbourne Investments Inc. - MarketBeat
Voleon Capital Management LP Takes $1.52 Million Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Nebula Research & Development LLC Purchases New Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. Reports Strong Growth Amid Challenges - TipRanks
Amgen (AMGN) Receives a Revised Price Target from UBS Analyst | - GuruFocus
Amgen (AMGN) Receives a Revised Price Target from UBS Analyst | AMGN Stock News - GuruFocus
Robots of Amgen - Amgen
Amgen's Better Than Expected Q1 Earnings Take Backseat As Eyes Are On MariTide Obesity Data - Benzinga
Amgen (AMGN): RBC Capital Maintains Rating, Lowers Price Target | AMGN Stock News - GuruFocus
Amgen (NasdaqGS:AMGN) Reports Strong Q1 Earnings With Revenue Increase To US$8 Billion - simplywall.st
Amgen’s Stelara biosimilar gets off to fast start - BioPharma Dive
Citigroup Adjusts Price Target on Amgen to $300 From $290 - marketscreener.com
Cantor Fitzgerald maintains neutral on Amgen stock, target at $305 - Investing.com
Cantor Fitzgerald maintains neutral on Amgen stock, target at $305 By Investing.com - Investing.com UK
Amgen Unusual Options Activity For May 02 - Nasdaq
Amgen (AMGN) Price Target Reduced by UBS Analyst | AMGN Stock News - GuruFocus
Amgen (AMGN) Surges After Beating Q1 Earnings Expectations - GuruFocus
Strong first-quarter product sales for Amgen - The Pharma Letter
Parvin Asset Management LLC Invests $1.46 Million in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Q1 2025 Earnings Call Transcript - Insider Monkey
Street View: Investor focus still on Amgen's weight-loss drug candidate - TradingView
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amgen Inc Stock (AMGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Santos Esteban | EVP, Operations |
Feb 19 '25 |
Option Exercise |
156.35 |
8,711 |
1,361,965 |
80,257 |
| Santos Esteban | EVP, Operations |
Feb 19 '25 |
Sale |
292.84 |
8,711 |
2,550,903 |
71,546 |
| REESE DAVID M | EVP & Chief Technology Officer |
Feb 19 '25 |
Option Exercise |
156.35 |
8,711 |
1,361,965 |
70,858 |
| REESE DAVID M | EVP & Chief Technology Officer |
Feb 21 '25 |
Sale |
304.44 |
25,225 |
7,679,524 |
36,922 |
| REESE DAVID M | EVP & Chief Technology Officer |
Feb 19 '25 |
Sale |
293.22 |
8,711 |
2,554,224 |
62,147 |
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):